GSK plc (GSK)
ValueMarkers Composite Index
67% above intrinsic value ($2)
GSK plc (GSK) — VMCI valuation read
Composite valuation read on GSK: VMCI 55/100 against a Healthcare sector median of 50. The 5-point above-median print is the headline number for GSK plc, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for GSK: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on GSK: GSK trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%); net debt to EBITDA of 0.3x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
GSK fell 3.4% over the trailing 7 days, with a -8.4% read on a 30-day basis.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.